Navigation Links
Jefferson neurosurgeons using new liquid treatment for wide-neck brain aneurysm
Date:1/30/2008

(PHILADELPHIA) Neurological surgeons at Jefferson Hospital for Neuroscience are among the first surgeons in the United States using an FDA-approved liquid system for treating wide-necked brain aneurysms, which could eventually replace current treatments.

Principal investigator Erol Veznedaroglu, M.D., associate professor of Neurological Surgery and director of the division of Neurovascular Surgery and Endovascular Neurosurgery, Thomas Jefferson University Hospital, is one of the few surgeons selected to explore the use of a liquid embolic (blocking) system to fill wide-neck brain aneurysms, which have a wide opening where the aneurysm arises from the artery or blood vessel. A brain aneurysm is a weakness in a major blood vessel that causes a portion of the vessel wall to balloon out. This abnormality puts an individual at risk should the aneurysm break open and bleed.

A wide-neck brain aneurysm is relatively uncommon and occurs in about 25 percent of persons with brain aneurysms, said Dr. Veznedaroglu. Wide-neck aneurysms can be difficult to treat both surgically (brain surgery to clip off the aneurysm) and endovascularly (treatment done from within the blood vessel), which are methods used to treat other types of brain aneurysms.

The potential benefit of the liquid embolic system may be the complete or partial blockage of the blood supply to the aneurysm, said Deborah L. August, M.D., MPH, director of Clinical Research in the department of Neurological Surgery, Jefferson. It may also help to correct or lessen some symptoms.

Current treatments for brain aneurysms include open brain surgery to clip the aneurysm and coil embolization or coiling, lessinvasive surgical procedure. For coiling, a catheter is inserted into an artery in the groin, then advanced into the affected artery in the brain. X-rays are used to guide the catheter into the artery.

Coils are the most commonly used embolization device but some wide-neck aneurysms have such a large opening that the coils may not stay inside the aneurysm sac, said Dr. Veznedaroglu. In this case, the coils can fall back into the blood vessel and block or partly block the blood flow.

Researchers noted they are not recruiting patients, as this is not a clinical study.

Rather, this is a Humanitarian Use Device which is used to diagnose or treat a disease or condition that affects fewer than 4,000 individuals in the United States per year and for which no comparable device is available.

The Food and Drug Administration (FDA) allows physicians to use such a device under a Humanitarian Device Exemption, when a device maker chooses not to do formal research studies to test a product as it would be used to treat a smaller population of patients.

Before the FDA gave the exemption, it looked at facts given by the maker of the device and decided that the likely risks of using the system are within reason, compared to the possible benefits of using this device and compared to other treatments for a wide neck aneurysm, said Dr. August. Research studies have not been done to show whether this system works for treating wide-neck aneurysms.

By filling the aneurysm sac or pocket with the liquid, blood flow into the aneurysm is blocked, helping to prevent the aneurysm from rupturing or increasing in size.

This treatment is done endovascularly and essentially consists of inserting a catheter into the blood vessel to cut off the blood supply. The material is delivered by slow-controlled injection through a very micro-size catheter into the aneurysm under x-ray visualization. The catheter is initially inserted into a vessel in the groin area and threaded to the vessel where the aneurysm is located. The material enters the aneurysm as a liquid through the catheter and then begins to solidify from the outside to the inside with final solidification or embolization occurring within five minutes.

To be eligible for such a procedure, a patient must 18 years or older, not have an intracranial stent and/or coils or severe liver or kidney disease. Women who are pregnant or nursing are also not eligible.


'/>"/>

Contact: Jeff Baxt
Jeffrey.Baxt@jefferson.edu
215-955-5507
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson scientists uncover role of cancer stem cell marker: controlling gene expression
2. Time Critical Diagnosis Task Force Convenes in Jefferson City
3. Jefferson scientists find protein helps pancreatic cancer cells evade immune system and spread
4. Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
5. Jefferson vascular surgeon heads national trial for torn aorta repair
6. Jefferson neuroscientists find early lead exposure impedes recovery from brain injury
7. Jefferson scientists see breast cancer gene activity from outside the body
8. Jefferson scientists uncover key pathway, potential drug targets in autoinflammatory disease
9. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
Breaking Medicine Technology: